About Predictive Oncology
Predictive Oncology is a company based in Eagan (United States) founded in 2002 was acquired by Renovaro in January 2024. Predictive Oncology has raised $43 million across 9 funding rounds from investors including Draper Triangle, Longitude Capital and Adams Capital Management. The company has 24 employees as of December 31, 2024. Predictive Oncology has completed 5 acquisitions, including BioDtech, Helomics and Quantitative Medicine. Predictive Oncology offers products and services including AI/ML Platform, 3D Tumor Models, and Clinical Testing Services. Predictive Oncology operates in a competitive market with competitors including Owkin, Formation Bio, AbSci, BigHat and Benchsci, among others.
- Headquarter Eagan, United States
- Employees 24 as on 31 Dec, 2024
- Stage Public
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Predictive Oncology Inc.
-
Annual Revenue
$1.62 M (USD)-0.24as on Dec 31, 2024
-
Net Profit
-$12.2 M (USD)12.75as on Dec 31, 2024
-
EBITDA
-$10.24 M (USD)10.09as on Dec 31, 2024
-
Total Equity Funding
$43 M (USD)
in 9 rounds
-
Latest Funding Round
$50.77 M (USD), Post-IPO
Oct 07, 2025
-
Investors
Draper Triangle
& 6 more
-
Employee Count
24
as on Dec 31, 2024
-
Investments & Acquisitions
BioDtech
& 4 more
-
Acquired by
Renovaro
(Jan 06, 2024)
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
IPO & Listings of Predictive Oncology
Predictive Oncology is a publicly listed company on the NASDAQ with ticker symbol POAI in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
Products & Services of Predictive Oncology
Predictive Oncology offers a comprehensive portfolio of products and services, including AI/ML Platform, 3D Tumor Models, and Clinical Testing Services.
Platform pairs AI with tumor samples to predict drug responses.
Models mimic human tumors for accurate drug response testing.
Services provide tumor drug-response and biomarker testing.
People of Predictive Oncology
Unlock access to complete
Unlock access to complete
Funding Insights of Predictive Oncology
Predictive Oncology has successfully raised a total of $43M across 9 strategic funding rounds. The most recent funding activity was a Post-IPO round of $50.77 million completed in October 2025. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Predictive Oncology
Predictive Oncology has secured backing from 7 investors, including venture fund and institutional investors. Prominent investors backing the company include Draper Triangle, Longitude Capital and Adams Capital Management.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Private equity firm focused on life science sector
|
Locked | Locked | Locked | |
|
Early-stage VC investments are made in US tech companies.
|
Locked | Locked | Locked | |
|
-
|
Locked | Locked | Locked |
Investor details for Predictive Oncology
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Predictive Oncology
Predictive Oncology has strategically engaged in corporate development activities, having acquired 5 companies. Notable acquisitions include BioDtech, Helomics and Quantitative Medicine.
Investment portfolio details for Predictive Oncology
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Tumor-specific in vitro 3D models are supplied for drug development.
|
Locked | Locked | 2014 | Locked | |
|
Quantitative Medicine is a biomedical analytics and computational biology company.
|
Locked | Locked | 2012 | Locked | |
|
Kits and services for protein solubility assessment are provided.
|
Locked | Locked | 2008 | Locked |
Complete acquisition details for Predictive Oncology
Transaction dates, acquired stakes, disclosed values, domains, and locations require an active premium plan.
- Transaction dates
- Acquired stakes
- Disclosed values
- Domains and locations
Verified entity values are shown only after access is granted.
Financial Statements - Predictive Oncology
Detailed financials for Predictive Oncology
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Predictive Oncology Comparisons
Peer comparison for Predictive Oncology
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Predictive Oncology
Predictive Oncology operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Owkin, Formation Bio, AbSci, BigHat and Benchsci, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
An agentic AI platform is developed for biomedical research insights.
|
|
| Locked | Locked | Locked |
AI-powered drug discovery platform for various diseases
|
|
| Locked | Locked | Locked |
AI-based technology is used for recombinant protein production in therapeutics.
|
|
| Locked | Locked | Locked |
Antibody therapies are developed through machine learning and synthetic biology.
|
|
| Locked | Locked | Locked |
AI platform used for extracting antibody data from scientific papers.
|
Detailed competitors of Predictive Oncology
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Predictive Oncology
Complete news archive for Predictive Oncology
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Predictive Oncology
Predictive Oncology was founded in 2002 and raised its 1st funding round 6 years after it was founded.
Predictive Oncology is headquartered in Eagan, United States. It is registered at Eagan, Minnesota, United States.
Carl Schwartz is the current CEO of Predictive Oncology.
Predictive Oncology is a funded company, having raised a total of $43M across 9 funding rounds to date.
As of Dec 31, 2024, the latest employee count at Predictive Oncology is 24.
Annual revenue of Predictive Oncology is $1.62M as on Dec 31, 2024.
Predictive Oncology was founded in 2002 and is headquartered in Eagan, United States. Operations focus on the healthcare sector, where an AI-driven platform supports cancer diagnostics and precision medicine development. Multi-omics data analysis and diagnostic tools are integrated to aid treatment planning and decision-making processes. Assessment and inventory systems for personalized therapies are also maintained through this technology.
Predictive Oncology's top competitors include Owkin, Formation Bio and XtalPi.
Predictive Oncology offers AI/ML Platform, 3D Tumor Models, and Clinical Testing Services.
Yes, Predictive Oncology is publicly traded on NASDAQ under the ticker symbol POAI.
Predictive Oncology has made 5 acquisitions, including BioDtech, Helomics, and Quantitative Medicine.
Predictive Oncology has 7 investors. Key investors include Draper Triangle, Longitude Capital, Adams Capital Management, Quaker Partners Management, and Birchmere Ventures.
The ticker symbol of Predictive Oncology is POAI on NASDAQ.